临床试验/NCT02445820

NCT02445820已完成不适用

The Association Between Hydroxyethyl Starch 130/0.4 and Acute Kidney Injury After Cardiopulmonary Bypass: a Single-center Retrospective Study

University of Liege0 个研究点目标入组 697 人开始时间: 2014年11月最近更新: 2015年10月30日

适应症

干预措施

试验速览

阶段: 不适用
状态: 已完成
发起方: University of Liege
入组人数: 697
主要终点: AKIN SCr

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

This study retrospectively assess the effect or using balanced hydroxyethyl sctarch (HES) 130/0.4 or a balanced crystalloid solution as a pump prime and for intraoperative fluid therapy on the risk of early acute postoperative kidney injury in adult cardiac surgery patients.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Retrospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Age ≥ 18 yo
•Having on pump cardiac surgery at CHU of Liège between April 2013 and June 2014

排除标准

•Off pump surgery
•Use of Blood or Albumin in the cardiopulmonary bypass priming solution
•Preoperative dialysis

研究组 & 干预措施

HES

Balanced HES 130/0.4 used as and pump prime and for intraoperative fluid therapy.

干预措施: HES (Drug)

Crystalloid

Balanced Crystalloid used as a pump prime and for intraoperative fluid therapy.

干预措施: Crystalloid (Drug)

结局指标

主要结局

AKIN SCr

时间窗: Forty eight hours

Stage of acute kidney injury using the Acute Kidney Injury Network Classification omitting the diuresis criteria.

次要结局

30-day mortality(30 days)
ICU stay(30 days)
Hospital stay(30 days)
AKIN SCr+UO(Forty eight hours)
Postoperative dialysis(30 days)
Respiratory complication(30 days)

研究者

发起方

University of Liege

申办方类型

Other

责任方

Principal Investigator

主要研究者

Jean François Brichant

Professor of Anesthesia and Intensive Care Medicine

University of Liege

相似试验

进行中（未招募）

1 期

Effects of hydroxyethyl starch 130/0.4 compared to a balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis - The 6S TrialSevere sepsis or septic shockMedDRA version: 9.1Level: LLTClassification code 10040070Term: Septic shockMedDRA version: 9.1Level: LLTClassification code 10053879Term: Sepsis syndrome

EUCTR2009-010104-28-FIDept. of Intensive Care, Rigshospitalet800

进行中（未招募）

不适用

orræn vísindarannsókn á notkun sterkjulausna í alvarlegri sýklasótt eða sýklasóttarlosti – 6S rannsókniSevere sepsis or septic shock

EUCTR2009-010104-28-ISDept. of Intensive Care, Rigshopitalet800

进行中（未招募）

不适用

Effects of hydroxyethyl starch 130/0.4 compared to a balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis - The 6S TrialSevere sepsis or septic shockMedDRA version: 13.1Level: PTClassification code 10040070Term: Septic shockSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 13.1Level: PTClassification code 10053879Term: Sepsis syndromeSystem Organ Class: 10021881 - Infections and infestations

EUCTR2009-010104-28-DKDept. of Intensive Care, Rigshospitalet800

已完成

不适用

Efficacy of hydroxyethyl starch (HES) 130/0.4 versus glucose solution in haemodilution therapy of idiopathic sudden hearing loss: a dose-finding, double-blind multicentre trialSudden hearing lossEar, Nose and Throat

ISRCTN26222607Fresenius Kabi Deutschland GmbH (Germany)210

已完成

2 期

Evaluation of balanced hydroxyethylstarch(HES 130/0.4) in upper abdominal surgery monitoring using the transpulmonal themodilution method: A prospective randomized trial

JPRN-UMIN000019930Sapporo medical university, Department of Anesthesiology40